0001415889-17-000182.txt : 20170203 0001415889-17-000182.hdr.sgml : 20170203 20170203185059 ACCESSION NUMBER: 0001415889-17-000182 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170201 FILED AS OF DATE: 20170203 DATE AS OF CHANGE: 20170203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baity Glenn CENTRAL INDEX KEY: 0001487100 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 17573609 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 form4-02032017_030250.xml X0306 4 2017-02-01 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001487100 Baity Glenn 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 false true false false EVP AND GC Common Stock 2017-02-01 4 M 0 21078 1.55 A 98141 D Common Stock 2017-02-01 4 S 0 31078 35.1497 D 67063 D Stock Option (right to buy) 1.55 2017-02-01 4 M 0 21078 0 D 2020-03-11 Common Stock 21078 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.315 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. /s/ Elizabeth Carter, Attorney-in-Fact 2017-02-03